Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this trial is to evaluate the dose response relationship of lonidamine and the primary efficacy endpoint, International Prostate Symptom Score (IPSS), in subjects with symptomatic benign prostatic hyperplasia (BPH).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
65 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Capable of understanding the purpose and risks of the study and sign a statement of informed consent
Male 65-80 years of age (or 40-80 with vasectomy). Vasectomized men must have documentation of azoospermia.
Presence of LUTS (lower urinary tract symptoms) for at least 3 months
Prostate volume measured by TRUS (transrectal ultrasound) > 30 cc
Qmax < 15 mL/sec when measured by uroflowmetry (minimum of 125 mL must be voided)
IPSS (International Prostate Symptom Score) > 12
PSA > 1.0 ng/mL
Must ensure and consent to use medically acceptable methods of contraception throughout the entire study with sexual partners of childbearing potential
Able to comply with the prescribed treatment protocol and evaluations
Prior treatment for BPH with alpha blockers and/or herbal supplements for the treatment of BPH in the past 2 weeks (alpha-blockers and/or herbal supplements for the treatment of BPH are not allowed during the study). Prior treatment with 5-alpha reductase inhibitors is allowed if discontinued at least 3 months prior to enrollment.
Prior surgery of the prostate (except biopsies; subject is eligible to enroll one month after full recovery from prostate biopsy.)
Current or past evidence of malignant disease of the prostate or prostatic intraepithelial neoplasia (For subjects with PSA between 4 - 10 ng/mL, prostate cancer must be ruled out to the satisfaction of the Principal Investigator. Subjects with PSA >10 ng/mL are excluded).
Active urinary tract infections (UTI)
Active cardiac, renal or hepatic disease as evidenced by:
Serum creatinine > 1.8 mg/dL
ALT or AST > 2.5x the upper limit of normal
History of active myocardial infarction, unstable cardiac arrhythmias, or stroke within 6 months prior to screening